Akorn Inc Reaffirms FY 2012 Outlook

Akorn, Inc. affirmed its previously issued fiscal 2012 outlook, with the exception of capital spending which has been updated to include the needs of Akorn India Private Limited. This revised outlook excludes the impact of vancomycin hydrochloride capsules and any new approvals after May 8, 2012. For fiscal 2012, the Company expects total revenues of $228-238 million, GAAP net income of $36-39 million, GAAP net income per diluted share of $0.33-0.36, Adjusted net income of $48-51 million, Adjusted net income per diluted share (EPS) of $0.44-0.46 and Adjusted EBITDA of $88-93 million.